Tai brings the strategic perspectives and external collaborations to Fast Track Initiative (FTI). FTI is a venture capital firm that invests in early-stage biotech companies. Since its inception in 2004, FTI has invested in 40 companies with a mission to translate academic researches into medicine, many times as a lead investor and with strong focus on newco creations. In 2020, it opened a Boston office. At FTI, Tai launched and leads the activities of the Boston office as a Partner. He sources and evaluates early-stage investment opportunities and supports portfolio companies through connections within the US and the Japanese life science communities. He serves as a Board of Director and a Board Observer for companies in Japan and US. As a member of GP, he also contributes to the fundraising activities of FTI Fund 3 and onward. Before FTI, Tai was an Investment Consultant at ARCH Venture, where he screened and evaluated early-stage therapeutics and diagnostics companies. Previously, he helped Takeda in early-stage oncology and regenerative medicine business collaborations and was a Junior Manager at McKinsey & Company. At McKinsey, he supported pharmaceutical companies to develop new business strategies and corporate strategies. Tai received a Master’s in Molecular Biology from the University of Tokyo and an MBA from the University of Chicago Booth School of Business.